glp 1 agonist and dpp 4 inhibitor GLP-1 receptor versus DPP-4 kidney and cardiovascular outcomes in clinical practice in type-2 diabetes DPP-4 inhibitors in the treatment

HbA 1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression

While such effects can lead to noticeable weight loss, they are only prescribed for individuals who meet specific medical requirements

As anticipated, patient preference is towards GLP-1 RA profiles associated with less frequent dosing, with once-weekly preferred to once-daily, with the latter preferred over twice-daily [123,124,125]

How These Meds Change the Game: Understanding Your New Appetite & Digestion Understanding how GLP-1 medications work helps in navigating the changes they bring to appetite and digestion

potential mechanisms

On the other hand, GLP-1 RAs were found to alter the gastric/small bowel motility and appetite/satiation via central or parasympathetic (vagal-mediated) pathways, leading to an increased incidence of retained gastric contents (RGCs) with the associated aspiration risk during the perioperative period [6,7,8]